DAIDZEIN: A REVIEW OF PHARMACOLOGICAL EFFECTS by Sun, Meng-Yao et al.
Sun et al., Afr J Tradit Complement Altern Med. (2016) 13(3):117-132 
http://dx.doi.org/10.4314/ajtcam.v13i3.15 
117 
 
DAIDZEIN: A REVIEW OF PHARMACOLOGICAL EFFECTS 
 
Meng-Yao Suna#, Ying Yeb#, Ling Xiaob, Khalid Rahmanc, Wei Xiad, Hong Zhanga* 
# these authors contributed equally to this work 
 
a Department of Pharmaceutical Botany, School of Pharmacy, Second Military Medical University, Shanghai 
200433, China. b Central Laboratory, Shanghai Seventh People’s Hospital, Shanghai 200137, China. c School 
of Pharmacy and Biomolecular Sciences, Faculty of Science, Liverpool John Moores University, Liverpool 
L3 3AF, England, UK. dDepartment of Nuclear Medicine, Shanghai Seventh People’s Hospital, Shanghai 
200137, China 
 
*Corresponding authors: E-mail: zhanghong@smmu.edu.cn  
  
 
 
Abstract  
 
Background: Daidzein is an isoflavone with extensive nutritious value and is mainly extracted from soy plants. It is also called 
phytoestrogen due to its structural similarity to the human hormone estrogen. However, daidzein is distinct from estrogen due to the 
specificity of the estrogen receptor (ER) complex. In recent years, the pharmacological properties of daidzein have been extensively 
investigated and considerable progress has been made. The present review aims to evaluate the pharmacological effects and 
mechanisms of daidzein as reported in scientific literature.  
Materials and Methods: Studies were identified as reported in PubMed, Elsevier, Scholar, and Springer over the last ten years and 
this resulted in the identification of 112 papers.  
Results: Daidzein is reported to play a significant role in the prevention and treatment of a variety of diseases such as cancer, 
cardiovascular disease, diabetes, osteoporosis, skin disease, and neurodegenerative disease. This pharmacological activity is 
attributed to various metabolites including equol and trihydroxy isoflavone. 
Conclusion: Daidzein appears to play a significant role in the prevention of a variety of diseases and has the potential of being used 
in a clinical setting. However, further research is needed to understand its molecular mechanisms and safety for use in humans. 
Key words: Plant, natural product, phytoestrogen, pharmacology 
 
 
Introduction 
 
Daidzein (4′, 7-dihydroxyisoflavone) whose chemical structure is shown in Figure 1 is a naturally occurring isoflavonic 
phytoestrogen belonging to the non-steroidal estrogens (Cassidy, 2003) and is mainly derived from the leguminous plants such as 
soybean and mung bean. It is also the major bioactive ingredient in traditional Chinese medicine Gegen (Wang et al., 2003) which is 
used frequently in the treatment of fever, acute dysentery, diarrhea, diabetes, cardiac dysfunctions, liver injury etc. (Wong et al., 
2011). The chemical structure of daidzein is similar to mammalian estrogens and it exerts a dual-directional function by 
replacing/interfering with estrogen and the estrogen-receptor (ER) complex. Therefore, daidzein exerts protective effects against 
some diseases which are linked to the regulation of estrogen such as breast cancer, osteoporosis, diabetes, cardiovascular diseases 
(Vitale et al., 2013). It also has a number of other biological activities independent of the ER such as anti-inflammation, anticancer, 
inhibition of oxidative damage, protection of skin and the nerves. These beneficial effects are mainly due to regulation of the 
immune response (Masilamani et al., 2012), scavenging of oxygen free radicals, inhibition of proliferation and so on. However, 
when daidzein is presented in the bound form “daidzin”, it becomes inactive and some metabolites of daidzein also display a similar 
pattern. 
The safety of phytoestrogens is rather controversial (Humfrey, 1998) as these may exert some negative effects on human health. 
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In addition, the general absorption of daidzein is poor and many studies have been conducted to improve the bioavailability of 
daidzein. For example, self-micro emulsifying drug delivery system (SMEDDS) was used to formulate and enhance oral absorption 
of daidzein (Shen et al., 2010). 
This review comprehensively evaluates the pharmacological properties of daidzein based on the summary of previously 
reported studies. 
 
 
 
Figure 1: Molecular structure of daidzein and its related isoflavones 
 
Pharmacological Effects 
Anticancer and anti-Breast Cancer activities 
 
Breast cancer is one of the most common malignant tumors in women which seriously threaten public health. Epidemiological 
studies have shown that the incidence of breast cancer in Asian women is lower than Western women due to the higher consumption 
of phytoestrogens (Adlercreutz, 2002). Thereby, the use of phytoestrogens may be a valid strategy in the prevention and treatment of 
breast cancer, via mechanisms including ER modulation and anti-angiogenesis (Liu et al., 2012a). Due to phytoestrogens being a 
significant constituent of daidzein its anticancer activity in breast cancer has attracted wide public attention.  
Tumor necrosis factor-α (TNF-α), a type of endogenous cytokine, is able to affect tumorigenesis and dysregulation of TNF-α 
production contributes to cancer risk (Locksley et al., 2001; Paul A et al., 2013). Daidzein plays a vital role in the regulation of 
mammary tumor cell invasion induced by TNF-α. There are two distinct signaling pathways reported to elucidate the molecular basis 
of this, with one being the nuclear factor-kappa B (NF-κB) signaling pathway. In breast cancer cells MDA-MB-231, daidzein 
treatment suppressed TNF-α induced NF-κB and AP-1, followed by a reduction in the secretion of uPA from breast cancer cells, thus 
inhibiting the migration of breast cancer (Valachovicova et al., 2004). The other pathway is the Hedgehog (Hh) signaling pathway. 
Daidzein antagonized these effects via suppressing Gli1 activation and expression, thereby inhibiting migration and invasion of ER 
negative MCF10DCIS.com human breast cancer cells. The metabolites of daidzein in vivo exerted stronger activity at the same 
concentration. It was found that matrix metalloproteinase (MMP)-2 and MMP-9 also participated in breast cancer invasion. Daidzein 
inhibited the activity and expression of MMP-9 induced by TNF-α via Hh/Gli1 signaling pathway (Bao et al., 2014). Another study 
on MDA-MB-231 determined its anti-invasive effects partially by reducing expression of MMP-2 (Magee et al., 2014).  
Moreover, daidzein displays anti-proliferative effects in breast cancer via cell cycle arrest in the G1 and G2/M phases and via 
the induction of apoptosis (Choi and Kim, 2008). The mechanism of apoptosis induced by daidzein is mitochondrial 
caspase-dependent pathway. Daidzein increased intracellular reactive oxygen species (ROS) generation which changed 
Sun et al., Afr J Tradit Complement Altern Med. (2016) 13(3):117-132 
http://dx.doi.org/10.4314/ajtcam.v13i3.15 
119 
 
mitochondrial transmembrane potential, leading to the release of cytochrome C. The reduced expression of anti-apoptotic proteins 
Bcl-2 and the increased expression of pro-apoptotic proteins Bax enhanced the release of cytochrome C. These factors further 
activated caspase-9 and caspase-7, resulting in eventual cell death (Jin et al., 2010).  
Interestingly, the effect of daidzein in attenuating breast cancer progression is more effective than tamoxifen (TAM), which is a 
clinical drug currently used for the treatment of breast cancer (Liu et al., 2012b). However, some studies have raised concern that 
daidzein may not be safe as it may stimulate proliferation of tumor cells (Choi and Kim, 2013), boosting existing breast tumors and 
suppressing the pharmaceutical effects of TAM. Therefore, females with breast cancer should be aware of the risks of potential 
tumor progression when taking soy products (de Lemos, 2001), as co-administration of TAM with daidzein is reported to produce 
tumors of greater size than observed with TAM alone. These findings suggest that simultaneous consumption of 
isoflavone with TAM may not be safe (Tonetti et al., 2007) due to its estrogen-like effects; meanwhile, possible detrimental effects of 
daidzein in breast cancer patients have also been raised in other studies (Messina and Loprinzi, 2001). In fact, as an estrogen 
responsive marker, daidzein had a slight but significant stimulatory effect on MCF-7 tumor progression at the lower concentration 
(Ju et al., 2006) but when used at high concentrations, it exhibited anticancer capacity and could play a cooperative role in the 
treatment of TAM. Although daidzein has anticancer activity in breast tumor, its application should be applied with caution (Gaete et 
al., 2012). 
 
Anti-Prostate Cancer 
 
Epidemiological studies on risk factors of prostate cancer indicate the importance of consumption of soy (Adaramoye et al., 
2015). As the main phytoestrogen of soy, daidzein displayed anti-proliferative properties in three prostate cancer cell lines (LNCaP, 
DU 145, PC-3) by the induction of cell cycle arrest at G0/G1 phase and the inhibition of angiogenesis via altering the expression of 
cyclin-dependent kinase-related pathway genes. Some of these genes are involved in DNA damage-signaling pathway, and also in 
the expression of angiogenesis genes, this can lead to the attenuation of growth factor EGF and IGF thus resulting in tumor growth 
inhibition (Rabiau et al., 2010). In androgen-dependent prostate cancer cells and LNCaP cells, the growth of prostate cancer is 
androgen dependent. Prostate androgen-regulated transcript-1 gene (PART-1) is a new gene that is responsive to androgens and could 
be potentially used as a biomarker of prostate cancer. Daidzein inhibited dihydrotestosterone (DHT)-induced expression of the 
PART-1 dose-dependently, implying that daidzein may have anti-androgen activity. Further in vivo studies have focused on the 
connection between prostate tumor growth and the inhibition of expression of PART-1 (Yu et al., 2003). Daidzein could induce 
apoptosis selectively in tumor cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apoptotic death. 
TRAIL is an endogenous anticancer agent, which induces disruption of mitochondrial membrane potential in the LNCaP cells thus 
promoting apoptosis (Szliszka and Krol, 2011). Studies in vitro and in vivo have suggested that daidzein can also be used as a radio 
sensitizer without inducing metastasis in lymph nodes as with genistein. The mechanism was AR-independent which enhance 
radiotherapy and inhibits tumor growth by down-regulating the expression of APE1/Ref-1 alter the activity of NF-κB and HIF-1α 
(Singh-Gupta et al., 2011). Overall, daidzein appears to have a role in prevention and treatment of prostate cancer. 
 
Inhibition of Other Cancers 
 
Daidzein was also reported to be beneficial in the treatment of colon cancer in that it produced biphasic effect on human colon 
cancer cells at different concentrations. Tumor suppressive effect on LoVo cells was by cell cycle arrest at G0/G1 phase and 
caspase-3 dependent apoptosis, which was irrelevant of differentiation (Guo et al., 2004). Using hepatocarcinoma SK-HEP-1 cells as 
the cell model, daidzein was reported to inhibit the growth of hepatocarcinoma cells, while having no effect on normal human 
hepatocytes. The apoptosis induced by daidzein was related to the regulation of Bcl-2 family via mitochondrial pathway (Park et al., 
2013a). Daidzein still exhibited antitumor effect in a number of murine and human neuroblastoma cell lines by the inhibition of cell 
proliferation, cell cycle arrest at G2/M phase, and promotion of cell apoptosis (Lo et al., 2007). Some derivatives of daidzein such as 
7, 3′, 4′-THIF a form of daidzein also have anticancer effect which has been demonstrated to play a chemo-preventive role in UVB 
induced non-melanoma skin cancer both in vitro and in vivo. The metabolite binds to Cot and MKK4 directly to inhibit the activity 
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of Cot and MKK4, which further markedly suppresses the expression of UVB-induced cyclooxygenase 2 (COX-2) ultimately,  
inhibiting the elongation and the number and volume of tumors. Although daidzein does not have any influence on COX-2 
expression, it could be used as a potential chemo-preventive agent in skin cancer due to its biotransformation (Lee et al., 2011a). 
7-(O)-carboxymethyl daidzein conjugated to N-t-Boc-hexylenediamine (cD-tboc) elicits antithyroid cancer and anti-epithelial 
ovarian cancer properties by augmenting cell apoptosis (Somjen et al., 2012; Green et al., 2009). 
 
 
Anti-Cardiovascular Diseases 
 
Cardiovascular diseases(CVD), such as coronary heart disease, atherosclerosis, and hypertension, can be classified as a kind of 
estrogen-related disorder (Dubey et al., 2004) since it is prevalent in post-menopause women. Conventional hormone replacement 
therapy (HRT) may not be safe since the outcome of clinical trials has reported adverse cardiovascular effects in experimental 
studies investigating vascular benefits (Ross et al., 2008). Daidzein is a potential candidate in the treatment of cardiovascular 
diseases and it exerts its mechanism by mainly regulating of blood lipid metabolism, endothelial dysfunction attenuation, decreasing 
in blood pressure and increasing antioxidant activity.  
In a study involving hypercholesteremic subjects, daidzein treatment for 6 months significantly decreased triglyceride (TG) 
concentration which is associated with ESR-β RsaI genotype while glucose and other lipids were not affected. In addition, uric acid, 
an independent risk factor of CVD, was also down-regulated by daidzein (Qin et al., 2014). In male middle-aged rats which included 
two groups, orchidectomized (Orx) and intact (IA), subcutaneous injection of high doses of genistein and daidzein decreased serum 
cholesterol levels (Sosić-Jurjević et al., 2007).  
Ovariectomy, which produces endothelium dysfunction including attenuation in endothelium-dependent vasorelaxation and 
nitric formation increase in oxidative stress and damage to endothelium integrity, can be alleviated by daidzein. It exhibited 
estrogen-like effect on endothelium-dependent vasorelaxation and inhibited caveolin-1 leading to an increase in nitric oxide 
bioavailability and as a result, daidzein improved endothelium dysfunction (Sharma et al., 2012). Another study in 
streptozotocin-induced diabetic rats also demonstrated that chronic supplement with daidzein ameliorated endothelium dysfunction. 
It significantly improved the vascular contractile and relaxation response activity endothelium-dependently by NO and 
prostaglandin-dependent pathways and it also inhibited lipid peroxidation (Roghani et al., 2013).  
Daidzein and its metabolite equol were also reported to play a significant impact on hypertension by controlling vascular 
smooth muscle tone via regulating a balance between vasodilator and vasoconstrictor, modulation of humoral systems and renal 
function, and this in turn lowers blood pressure. However, the anti-hypertension effect of daidzein has only been demonstrated in 
animal models currently, and it still needs further validation in human clinical trials (Martin et al., 2008). The effect of daidzein on 
catecholamine synthesis and secretion also contributed to a reduction in the risks of CVD (Yanagihara et al., 2014; Liu et al., 2007). 
Pretreatment with daidzein in a rat ischemia/reperfusion model markedly reduced myocardial injury induced by ischemia 
reperfusion, such as improved myocardial contractile dysfunction, inhibition of myocardial apoptosis, and decreased myocardial 
infarct size. These beneficial effects could be largely due to the activation of NF-κB, which regulated expression of inflammatory 
cytokine by its antioxidant activity (Kimet al., 2009). However, the protective effect of daidzein on CVD is different because the 
ability is different for people to produce equol from daidzein which plays an important role in decreasing arterial stiffness and 
anti-atherosclerotic effects (Gil-Izquierdo et al., 2012). 
In general, daidzein exhibits protective action on CVD risk factors although the mechanisms are not clearly defined. It has the 
potential to be an alternative agent for the therapy of CVD, especially in post-menopause CVD women (Gencel et al., 2012). 
However, the absorption and bioavailability of daidzein is poor when given in oral administration, but daidzein-loaded solid lipid 
nanoparticles (SLNs), a new type of daidzein, exerts a better effect on cardiovascular system and it has the potential  to be used in 
the treatment of cardio-cerebrovascular diseases in the future(Gao et al., 2008). 
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Anti-Osteoporosis 
 
Osteoporosis is a disease characterized by increased bone loss and fracture risks (Body, 2011). It is also common in menopausal 
women due to estrogen deficiency. Pretreatment with estrogen may prevent osteoporosis by affecting osteoclast formation and 
activation through promoting TGF-mediated apoptosis, which is produced by osteoblasts (Hughes et al., 1996). Estrogen could also 
directly induce osteoclast apoptosis by binding to ERα in osteoclast and then altering the expression of FasL (Novack, 2007). 
Although HRT is effective in the treatment of osteoporosis, its potential negative effects such as breast cancer cannot be ignored 
(Lewis, 2009). 
As a phytoestrogen, daidzein displays estrogen-like effects. Moreover, equol, a metabolite of daidzein, showed stronger 
estrogenic activity than other isoflavones. Therefore, daidzein is unique compared to other isoflavones and has the potential to treat 
osteoporosis (Setchell et al., 2002). Daidzein can also inhibit bone reabsorption. A study on cultured osteoblasts from long bones of 
young female piglets showed that the low concentration of daidzein (1 nM) promoted differentiation of osteoblast via ERβ pathway, 
increased ALP activity and mineralization. Furthermore ERβ was evidenced by increase in the secretion of osteoprotegerin (OPG) 
and RANK ligand (RANK-L) which are involved in osteoclastogenesis and runx2/Cbfa1, thus daidzein plays a vital role in 
osteoblast differentiation and function (De Wilde et al., 2004). Moreover, daidzein inhibited differentiation and activation of 
osteoclast largely by activating caspase 3 to induce osteoclast progenitor apoptosis. The expression of osteoclastogenesis inhibitory 
factor (OCIF) in osteoblast-like cells downregulated secretion of some factors such as OPG, also associated with the inhibition of 
osteoclast differentiation. The mechanism was by ERS, mainly by ERβ pathway in porcine bone marrow cells (Rassi et al., 2002). In 
addition, daidzein exhibited bone protection and bone resorption inhibition indirectly by stimulating secretion of calcitonine, which 
is a kind of hormone produced by Thyroid C cells, inhibiting the activity of osteoclasts and inducing osteoblast-line cell proliferation. 
This study was conducted in ovariectomized (Ovx) male rats and it provided a feasible way in the treatment of male osteoporosis 
(Filipović et al., 2010). In vivo model using parietal bone defects from New Zealand white rabbits has demonstrated the effect of 
daidzein on bone formation in collagen matrix. There were 602% more new bone formation in collagen matrix with daidzein when 
compared to the control, suggesting that daidzein stimulated new bone formation and it could be applied to bone grafting (Wong and 
Rabie, 2009). 
Mathey et al. (2007) pointed out that daidzein treatement together with equol improved not only total femoral BMD but also 
bone strength in Ovx rat. Thus, the addition of fructooligosaccharides (FOS) or live microbial to promote intestinal bacterial 
metabolism of daidzein could markedly enhance the protection action of daidzein on bone. Combination of daidzein with high dose 
of Ca also augmented the protective effect on bone mass and biomechanical strength, although their mechanisms were different 
(Fonseca and Ward, 2004). When daidzein was used in combination with kiwifruit, the effect on reducing bone loss caused by 
estrogen deficiency was little while exerting no effect on the production of equol (Tousen et al., 2014).  
However, some side effects of daidzein such as low bioavailability, unfavorable metabolism and uterine estrogenicity have 
limited its clinical application. Recently, a number of daidzein analogs were found to exert protective impact on osteoporosis by 
promoting of differentiation in bone marrow-derived mesenchymal stem cells (BMSCs) and adipose-derived stromal stem cells 
(ASC) ER-independently. For example, isoformonetin, a methoxy daidzein, prevented osteoblasts from apoptosis and controlled 
bone loss (Strong et al., 2014; Srivastava et al., 2013). 
 
Anti-Diabetic Activity 
 
In recent years, due to an increase in living standards, diabetes has become a worldwide epidemic disease. International 
Diabetes Federation (IDF) report a persistent growth in diabetes incidence and it is projected that by the year 2030, there will be 439 
million diabetics in the world. Moreover, about 90% of diabetic patients diagnosed had type II diabetes (Getek et al., 2014). 
Undoubtedly, finding an effective method to treat diabetes is urgent. 
Soy phytoestrogen plays an important role in Type 2 diabetes. Daidzein is one of the most bioactive components exerting 
anti-diabetic activity in soy phytoestrogen (Jayagopal et al., 2002). Both in vitro and in vivo experiments have proved 
anti-hyperglycemic effect of daidzein. In Type 2 diabetic cell model, L6 myotubes, daidzein stimulated glucose uptake through 
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promoting AMPK phosphorylation to increase glucose transporter 4 translocation to PM of muscle cells, which in turn led to glucose 
homeostasis insulin-independently. In vivo studies used KK-Ay mice and db/db mice as Type II diabetic animal model. It has been 
observed that daidzein controlled increased blood glucose levels to exhibit its anti-hyperglycemia effect (Cheong et al., 2014). 
Another study in C57BL/KsJ-db/db mice found that the anti-diabetic effect of daidzein in type 2 diabetes was also associated with 
liver glucose and lipid metabolism by modulating related enzyme activities. Genistein and daidzein treatment regulated blood 
metabolism by significantly lowering the ratio of glucose-6-phosphatase (G6Pase)/GK and phosphoenolpyruvate carboxykinase 
(PEPCK) in the liver of db/db mice while had no effect on the levels of plasma insulin and C-peptide, but increased the ratio of 
insulin/glucagon. Insulin resistance is related to hepatic lipid accumulation, genistein and daidzein dramatically lowered the plasma 
FFA level to decrease β-oxidation via carnitine palmitoyltransferase (CPT-1) in type 2 diabetic mice. As a result, it improved the 
metabolism of liver lipid, and then controlled blood glucose concentration (Ae Park et al., 2006). To conclude, daidzein prevented 
against Type II diabetes and has the potential to be developed as a potent anti-diabetic phytochemical medical agent. 
Daidzein could also play a beneficial role in regulation of fasting blood glucose level in type I diabetes which is also known as 
insulin dependent diabetes (IDDM). Insulin deficiency is the main pathogenetic mechanism responsible for type I diabetes. Daidzein 
treatment induced survival of pancreatic β-cells and insulin secretion while having no effect on glucagon in non-obese diabetic 
(NOD) mice, an animal model of human type 1diabetes. The regulation of hepatic glucose and lipid metabolism by altering a series 
of related enzyme activity has also been demonstrated, the mechanism of which is similar to the type II diabetes, such as reducing 
activities of G6Pase, PEPCK, fatty acid beta-oxidation and CPT and increasing activities of malic enzyme and G6PD (Choi et al., 
2008). The molecular basis of daidzein regulating glucose and lipid metabolism is activation of peroxisome proliferator-activated 
receptors(PPAR) and further regulation of PPAR-α-mediated and PPAR-γ-mediated gene expression involved in glucose and lipid 
metabolism (Mezei et al., 2003). Daidzein also suppressed up-regulation of postprandial blood glucose levels by inhibiting the 
activity of carbohydrate digestive enzymes, α-glucosidase and α-amylase (Park et al., 2013b). 
Taking daidzein and hemin together might decrease the expression of caveolin, inhibiting RAAS system and enhancing the 
level of renal nitric oxide in the wistar rat mode (Katyal et al., 2013). Comprehensive factors have to be taken into consideration as 
combined therapy in diabetes may protect kidney and related systems such as renin-angiotensin system (RAS). 
 
Anti-Aging Activity 
 
Daidzein has a role in the cosmetic industry due to its ability to prevent skin aging and photo-damaging. Skin aging is primarily 
associated with collagen reduction in the dermis, type I and type III collagens are the main component of extracellular matrix (ECM) 
which is vitally important in maintenance of the dermis structure. 
Transforming growth factor (TGF-β) mediated by smad is involved in the regulation of ECM (Choi et al., 2007). It has been 
demonstrated in vitro and in vivo that daidzein promoted collagen deposition by stimulating collagen synthesis via up-regulating the 
expression of type I pro-collagen and inhibiting collagen degradation via down-regulating the levels of MMP1 (matrix 
metalloproteinase1), and MMP2. This collagen metabolic regulation was mediated by TGF-β/smad signal pathway, 
phosphorylated-smad2, smad3 and TGF-β was significantly higher in the daidzein-treated cells when compared to the control (Zhao 
et al., 2015). Exposure to solar UV radiation for a long time, in particular UVB radiation, accelerates skin aging due to induced 
production of oxygen free radicals in a study of pig skin model which is similar to the human skin. The photo-protection effect of 
daidzein was demonstrated by evaluating colorimeter-measured erythema and photo-damaged cell numbers after solar-simulated 
ultraviolet (ssuv) irradiation (Lin et al., 2008). It was widely believed that daidzein exhibited photo-protection due to its antioxidant 
activity by clearing free radical of keratinocytes induced by UV radiation (Huang et al., 2008a). However, another study found the 
primary mechanism related to ERβ. S-equol is a gut metabolite of daidzein which prevents skin from natural or photo-aging via 
activating ERβ directly. The selective activation of ERβ increased levels of the antioxidant enzymes which protected skin from 
harmful oxygen-free radical injury and reduced levels of snail which modulated proliferation and migration of keratinocyte, resulting 
in an increase in the expression of type I and type III collagens (Jackson et al., 2011). Retinoid a vitamin A derivative has been used 
to treat skin-aging and it enhances collagen accumulation in the dermis, however retinoid-induced skin irritation can lead to 
epidermal hyperplasia. Co-treatment with daidzein inhibited these side effects of retinoid (Varanl et al., 2004). Daidzein could bind 
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to RAR and RARγ directly to increase the activity of RAR and RARγ, further exerting photo-protective effects. Moreover, it 
inhibited the activity of matrix metalloproteinase-9 (Oh et al., 2013). Hyaluronic acid (HA) was another major ingredient present in 
the epidermis and dermis, maintaining hydration and inhibiting elasticity loss, which can prevent skin from aging. HA exhibits 
age-dependent loss similar to that observed with collagen. Both in vitro and in vivo studies demonstrated that daidzein stimulated the 
production of cutaneous HA (Miyazaki et al., 2002). Bifidobasterium-fermented (BE) soy milk extract mainly containing genistein 
and daidzein enhanced HA production and improved the elasticity and viscoelasticity of mouse skin, while non-fermented (SME) 
soy milk extract did not exert the stimulative effect of daidzein on HA production (Miyazaki et al., 2003). 
Based on the ability of daidzein to protect the skin, the ability of percutaneous absorption of daidzein to achieve stable 
treatment concentration was studied. The results indicate that daidzein showed higher skin deposition in a non-ionized form than in 
an ionized form. Although aglycone mixture and PEG400 can improve skin permeation, the ability of daidzein absorption by the 
transdermal route was very weak (Minghetti et al., 2006), however, repeated transdermal application of daidzein could improve its 
concentration in plasma (Vänttinen and Moravcova, 2001). 
 
Antioxidant Activity 
 
Daidzein is a natural antioxidant and there are two mechanisms mediating its antioxidant activity. First, in liposomal 
membranes, daidzein inhibited lipid oxidation by clearing radical directly and impeded the migration of radicals by changing the 
fluidity of membrane via binding to it (Liang et al., 2008). Secondly, daidzein exerted antioxidant effect indirectly via improving the 
activity of anti-oxidative enzymes (AOE) which including catalase, glutathione peroxidase (GPx) and superoxide dismutase (SOD) 
(CuZn-and Mn-SOD) (Kampkötter et al., 2008a). The effect of daidzein on modulating the expression level of AOE in a study of rat 
hepatoma H4IIE cells reached the maximum at the concentration of 300 micromol/L. Transfection experiments suggested that 
daidzein can up-regulate the expression of catalase mRNA via activating catalase promoter region directly. However, the oxidative 
stress induced by H2O2 was not affected by daidzein through this mechanism and daidzein itself exhibited a weak antioxidant 
capacity (Röhrdanz et al., 2002). Furthermore, it was demonstrated that daidzein significantly enhanced the activity of catalase and 
the expression of catalase gene by acting on the proximal part of the catalase promoter (Kampkötter et al., 2008b). In general, 
changes in AOE system are more important than daidzein itself in exerting antioxidant activity. 
Daidzein was reported to be beneficial to animal health due to its antioxidant activity. In streptozotocin-induced diabetic rats, 
daidzein down-regulated the increased concentration of MDA, a product of lipid peroxidation and stimulated the inhibited activity of 
SOD to attenuate the oxidative stress including the prevention of vascular dysfunction (Roghani et al., 2013). The administration of 
flutamide resulted in androgen (AE) deficiency which lowered the levels of endogenous AOE in Wistar rats. Daidzein exerted 
protective effect by restoring the levels of AOE and AE to normal in a dose dependent manner (Lateef et al., 2012). It was observed 
in vitro that some metabolites of daidzein such as O-DMA and equol generally exhibited stronger antioxidant potential by increasing 
the activity and expression of catalase and SOD compared to daidzein alone (Choi and Kim, 2014). 3′-OH-daidzein and 
6-OH-daidzein, another two metabolites of daidzein were also more effective than daidzein (Liang et al., 2008). Thereby, these 
antioxidant metabolites might contribute to the antioxidant properties of dietary isoflavonone. In addition, gamma irradiation on 
soybean will significantly improve concentration of genistin and daidzein and the antioxidant activity at dose up to 10 kGy (Popović 
et al., 2014). 
 
Anti-Inflammatory Activity 
 
Failure to clear apoptotic cells in time can lead to the initiation of inflammatory diseases. Efferocytosis is defined as clearance 
of apoptotic cells and daidzein augmented efferocytosis capability of macrophage cell RAW264.7 by up-regulating the 
expressionofTG2 which is needed for effective engulfment during efferocytosis. The increased TG2 stimulated phosphorylation of 
Erk to activate Rac1 and the down-regulation of mitochondrial membrane potential eventually enhances efferocytosis (Yen and Yang, 
2014).   
 Daidzein could also inhibit activation of NF-κB which is a type of transcription factor, closely related to inflammation by 
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regulating the transcriptional activation of array of target genes including pro-inflammatory mediators, such as iNOS, COX-2, 
various cytokines, chemokines, and adhesion molecules. It can be activated by many stimuli such as TNF-α (Pahl, 1999). 
TNF-α-treated murine lung MLE-12 epithelial cells were the cell models to elucidate the underlying anti-inflammatory mechanism 
of daidzein. Daidzein markedly decreased the level of TNF-α-induced protein poly-adenosine diphosphate-ribosylation (PARylation) 
by binding to PARP-1 directly, resulting in the suppression of the transcription of pro-inflammatory genes such as NF-κB, which 
further inhibited the expression of chemokine Cxcl2 (Li and Pan, 2014). Daidzein was effective in the treatment of periodontal 
inflammation which was induced by lipopolysaccharide (LPS) from Prevotella intermedia, a pathogen. In P. intermedia LPS-treated 
RAW264.7 cells, daidzein significantly inhibited the production of NO and IL-6 through NF-κB signal pathway via suppressing 
degradation of IκB-α and iNOS activation to alter the function of NF-κB, and STAT1 plays a cooperative role with NF-κB in this 
process via suppressing STAT1 phosphorylation. These reduced secretion of inflammatory factors from macrophage contributed to 
anti-inflammatory effect of daidzein in the periodontium (Choi et al., 2012).  
As for obesity-related adipose inflammation, daidzein was reported to activate PPARγ directly to promote differentiation of 
adipocytes and regulate expression of adipokine. Mainly, it up-regulated the expression of adiponectin and further decreased the 
expression of pro-inflammatory factor TNF-α and MCP-1 which plays an important role in suppressing macrophage infiltration in 
adipose tissue. Moreover, daidzein inhibited hypertrophy in adipocyte size and it is apparent that daidzein can improve 
obesity-related inflammation which is related to insulin resistance (Sakamoto et al., 2014). In addition, daidzein is still used in the 
treatment of inflammatory damage of the skin caused by UVB or 12-O-tetradecanoylphorbol-13-acetate (TPA). Keratinocytes and 
fibroblasts were used to investigate UVB induced cutaneous inflammation, and the result indicated that daidzein suppressed 
macrophage infiltration to the dermis and epidermis induced by UVB, further decreasing the production of ROS, the expression of 
pro-inflammatory mediators such as iNOS and COX-2 and the pro-inflammatory factors such as TNF-α via inhibiting the 
mitogen-activated protein kinase (MAPK) signaling pathway (Lee et al., 2014).Besides, daidzein suppressed TPA-induced skin 
inflammation by reducing the activation of NF-κB, and the expression of IL-6,TNF-αand COX-2 (Khan et al., 2012). Consequently, 
daidzein has the potential to improve therapy in inflammatory diseases in the future.  
 
Neuroprotective Activity 
 
Daidzein has also been evaluated for its protective effect against neurodegenerative diseases. Stroke morbidity rate is high in 
the world, and currently there is no suitable drug for its treatment. It is well known that stroke is associated with brain injury which 
can result in lasting damage to the body. Rats were used to demonstrate the neuroprotective effect of daidzein after stroke. The 
results indicated that when treated with daidzein, rats expressed fewer deep slips in the skilled ladder rung walking task compared to 
rats treated with no daidzein, suggesting that daidzein was effective in neuroprotection and function recovery after stroke, although 
the mechanism is not clearly defined (Stout et al., 2013). There were three possible hypotheses reported to explain this 
neuroprotective effect of daidzein. Firstly, daidzein binds to ERβ and G-protein-coupled receptor 30 (GPR30) directly to inhibit 
neuron cell apoptosis by mitochondrial caspase-dependent pathway (Kajta et al., 2013). Secondly, daidzein induces the transcription 
of arginase 1 (Arg1), further stimulating the survival and regeneration of neuron in central nervous system (CNS) by inhibiting MAG 
cAMP independently (Ma et al., 2010). Thirdly, daidzein activates PPARγ by regulating nuclear translocation from cytoplasm to 
inhibit neural cells death and promote axon cells maturation. Moreover, the activation of PPARγ is not related to ligand binding of 
daizein (Hurtado et al., 2012). In addition, Yang et al. (2012) showed that daidzein may induce phosphorylation of Src kinase, further 
activating Src-protein kinase C delta (PKCδ)-ERK signal pathway to promote axon growth of rat dorsal root ganglion (DRG) 
neurons. In cerebellar granule cells, daidzein could reduce oxidative damage of mitochondria by down-regulation of the ROS levels, 
and thus subsequent inhibition of apoptosis (Atlante et al., 2010). 
It is well known that hippocampus is mainly responsible for learning and memory. Scopolamine induced memory damage in 
male rats can be ameliorated by daidzein through ER and some behavioral tests have demonstrated this (Kim et al., 2010). Axon 
formation and extension was stimulated with daidzein treatment in hippocampus neuron. Daidzein activated ERβ in the membrane, 
further promoting phosphorylation of PKCα in growth-associated protein GAP-43. Eventually, the growth of axon in hippocampus 
neuron led further to the modulation of learning and memory ability (Wang et al., 2008). When exposed to a very high-fat diet, 
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animals would suffer from high fat diet-induced energy metabolism imbalance which resulted in apoptosis and gliosis in the adult 
hippocampus. Pretreatment with daidzein enhanced cell proliferation, while inhibited apoptosis and gliosis by down regulating the 
expression of ERα, caspase3, GFAP and IBA1, in the hippocampus (Rivera et al., 2013). 
In vitro, daidzein inhibited aggregation of Aβ and in the used pheochromocytoma PC12 neuronal cellular model, treatment with 
daidzein, Aβ-induced cytotoxicity was also inhibited. Moreover, the co-treatment in the cultures with baicalein further enhanced this 
effect. Therefore, daidzein may play a significant role in the treatment of Alzheimer's disease in the future (Choi et al., 2013). 
 
Other Activities 
 
In addition to the described pharmaceutical activities, daidzein exhibits other beneficial effects. Menopausal women are at 
higher risk of multiple problems like heart disease and bone loss which was mentioned earlier due to estrogen deficiency. The 
incidence of hot flashes is also high in that about 75% of postmenopausal women experience this leading to a reduction in their 
quality of life. Ricciotti HA found isoflavone supplement which is rich in daidzein significantly ameliorated hot flashes in a study of 
twenty-four postmenopausal women (Ricciotti et al., 2005). Daidzein was also effective in pulmonary fibrosis induced by bleomycin 
in rats, inflammation and alveolar epithelial cell apoptosis was mainly responsible for pulmonary fibrosis. Daidzein reversed this 
effect by decreasing the level of proteinase activated receptor 2 and TGF-β (Soumyakrishnan et al., 2014). In addition, daidzein can 
inhibit the over-secretion of mucin from airway epithelial cells which would cause respiratory diseases (Lee et al., 2011b). In OVX 
rats, daidzein was reported to stimulate cadmium excretion to avoid the damage of heavy metal accumulation on renal function (Om 
& Shim, 2007). It was reported that daidzein treatment in male Balb/cJ mice alleviated anxiety, increased locomotor activity and 
decreased their social behavior including aggression and sexual behavior, the mechanism may be related to ER (Zeng et al., 2010). 
Daidzein supplementation to the mother also affected social behavior of female offspring. Daidzein reduced the expression of ERα in 
the brain, resulting in behavioral masculinization in adult female mice while it had no effect on anxiety (Yu et al., 2010). 
 
Conclusion 
 
Daidzein as a plant extract has been extensively investigated recently. In this paper, pharmacological effects of daidzein have 
been reported and these include anticancer, anti-cardiovascular diseases, anti-osteoporosis, anti-diabetes, anti-inflammation, 
antioxidant, anti-aging activity, neuroprotective activity and some other activities as presented in Figure 2. Over the years, 
conventional HRT has been used to ameliorate menopause symptoms clinically but unfortunately various complications such as 
breast cancer have limited its clinical usage. Daidzein was discovered to have a structure similar to estrogen and to be selective to the 
ER. Currently it is being widely used in the treatment of some diseases and there is hope for further development in its clinical 
application. However, the mechanisms of action remain uncertain and its poor bioavailability limits its application, and some 
possible side effects of daidzein have been reported. Besides promotion of tumor growth mentioned earlier, daidzein can cause 
erectile dysfunction due to down-regulation of androgen and alternation of penile cavernosal structures (Pan et al., 2007; Huang et 
al., 2008a). Thus, the details of the mechanisms involved need to be further clarified to reduce the side effects.  
Some bio-transformations in the body or synthetic analogues of daidzein maybe more effective on health or/and less toxic, 
such as isoformonetin and 7, 3′, 4′-THIF. Although some bioactive analogues of daidzein have been identified for their benefits on 
human health, many other potential metabolites remain unknown. Therefore, it is necessary to find novel effective substances based 
on the structure of daidzein. In addition, it is also crucial to enhance the absorption and bioavailability of daidzein, which may be 
realized via the appropriate way of administration or drug modification according to its physicochemical properties and 
pharmacokinetic parameters. Further studies are needed before daidzein can be widely promoted for use in clinical settings. 
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Figure 2: The pharmacological effects of daidzein 
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